Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Weighing Fixed Brand Vaccine Allocation for Each Medical Institution: Official
November 25, 2020
- COVID-19 Vaccine Distribution Will Be Undertaken by Wholesalers with Certain Track Records: Minister
November 25, 2020
- Takeda’s ALK Med, 1st Male Indication for HPV Vaccine, Lynparza’s Pancreatic Cancer Use Up for PAFSC Review on Dec. 4
November 24, 2020
- 1st Humira Biosimilar to Join NHI Price List on Nov. 25
November 24, 2020
- MHLW to Evaluate Suspected Adverse Reactions to COVID-19 Vaccines More Frequently than Usual: Minister
November 24, 2020
- Govt Won't Disclose Plans for Excess COVID-19 Vaccines: Health Minister
November 24, 2020
- LDP Going into Tax Reform Debate for FY2021
November 20, 2020
- Fully Implement Off-Year Drug Re-Pricing: LDP Fiscal Consolidation HQ
November 20, 2020
- Lower House Passes Immunization Act Amendment Bill
November 20, 2020
- PAFSC Likely to Skip Review of Ono’s Cancer Cachexia Drug Yet Again
November 20, 2020
- Lilly’s Galcanezumab Up for PAFSC Review for Migraine Prevention on Dec. 2
November 19, 2020
- MHLW Mulls Health Follow-Up on 10,000-Plus COVID-19 Vaccine Recipients
November 19, 2020
- MHLW Expects Use of Dry Ice-Fitted Cooling Boxes to Deliver Ultracold Chain-Required COVID-19 Shots: Official
November 19, 2020
- Chuikyo Healthcare, Payer Reps Still Divided Over Off-Year Re-Pricing Debate
November 19, 2020
- Japan Should Consider Mass Vaccinations for COVID-19: JMA Official
November 18, 2020
- MHLW Collecting Evidence to Discuss Introduction of Medical Fee for Hospital Formularies in FY2022 Reimbursement Reform
November 18, 2020
- Takeda Prepping for Japan Trial of Moderna COVID-19 Vaccine: MHLW Official
November 18, 2020
- Drug Makers Disclosing as Much Cost Info as Possible in Price Negotiations, JPMA Chief Rebuts Concerns Aired in Project Review
November 17, 2020
- Experts Urge Transparency for DPO/CEA Organization, Stringent Pricing for Cost-Based Products: Govt Project Review
November 17, 2020
- With Consensus on 13 Topics Delayed by COVID-19, ICH Expected to Restrict Selection of New Topics at Virtual Assembly
November 16, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…